5-fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5′-deoxy-5-fluorouridine in patients with hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 25, 2005, Pages 3944-3947

  Zheng, Jin Fang ^a   Wang, Hai Dong ^a  

^a HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

5 fluorouracail; 5 deoxy 5 fluorouridine; Apoptosis; Hepatocellular carcinoma

Indexed keywords

DOXIFLURIDINE; FLUOROURACIL;

ADULT; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER TISSUE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; NICK END LABELING; PREOPERATIVE TREATMENT; STATISTICAL SIGNIFICANCE; TUMOR CELL;

EID: 22644441302     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i25.3944     Document Type: Article

References (30)

1. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14: 703-709
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35(5 Suppl 2): S72-78
3. Kobayashi N, Kubota T, Watanabe M, Otani Y, Teramoto T, Kitajima M. Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. J Infect Chemother 1999; 5: 144-148
4. Hiroyasu S, Shiraishi M, Samura H, Tokashiki H, Shimoji H, Isa T, Muto Y. Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. Jpn J Clin Oncol 2001; 31: 65-68
5. Ito K, Okushiba S, Morikawa T, Kondo S, Katoh H. Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer. Gan To Kagaku Ryoho 2004; 31: 55-59
6. Min JS, Kim NK, Park JK, Yun SH, Noh JK. A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer. Ann Surg Oncol 2000; 7: 674-679
7. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
8. Takiguchi N, Fujimoto S, Koda K, Oda K, Okui K, Nakajima N, Miyazaki M. Postoperative adjuvant chemotherapy is effective in gastric cancer with serosal invasion: significance in patients chosen for multivariate analysis. Oncol Rep 2002; 9: 801-806
9. Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Xiao YS, Shi YH, Li XM, Sun QM, Liu YK, Ye SL. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Clin Cancer Res 2003; 9(16 Pt 1): 6030-6037
10. Hata Y, Takahashi H, Sasaki F, Ogita, M, Uchino J, Yoshimoto M, Akasaka Y, Nakanishi Y, Sawada Y. Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5′-deoxy-5-fluorouridine (5′DFUR) on breast cancer. Breast Cancer 2000; 7: 37-41
11. Bajetta E, Di Bartolomeo M, Somma L, Del Vecchio M, Artale S, Zunino F, Bignami P, Magnani E, Buzzoni R. Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. Eur J Cancer 1997; 33: 687-690
12. Zufia L, Aldaz A, Castellanos C, Giraldez J. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Ther Drug Monit 2003; 23: 221-228
13. Nassim MA, Shirazi FH, Cripps CM, Veerasinghan S, Molepo M, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R. An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med 2002; 10: 513-516
14. Ozawa S, Hamada M, Murayama N, Nakajima Y, Kaniwa N, Matsumoto Y, Fukuoka M, Sawada J, Ohno Y. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver. Cancer Chemother Pharmacol 2002; 50: 454-458
15. Xu Y, Kajimoto S, Nakajo S, Nakaya K. Beta-hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway. Oncology 2004; 66: 67-75
16. Barnett KT, Fokum FD, Malafa MP. Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res 2002; 106: 292-298
17. Huesker M, Folmer Y, Schneider M, Fulda C, Blum HE, Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology 2002; 36(4 Pt 1): 874-884
18. Warmann S, Gohring G, Teichmann B, Geerlings H, Pietsch T, Fuchs J. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2003; 23: 4607-4611
19. Tono T, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 2000; 88: 1549-1556
20. Guo WJ, Yu EX. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000; 73: 1091-1097
21. Nagata T, Nakamori M, Iwahashi M, Yamaue H. Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5′-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. Eur J Cancer 2002; 38: 712-717
22. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999; 80: 1726-1733
23. Kanyama H, Tomita N, Yamano T, Miyoshi Y, Ohue M, Fujiwara Y, Sekimoto M, Sakita I, Tamaki Y, Monden M. Enhancement of the anti-tumor effect of 5′-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells. Jpn J Cancer Res 1999; 90: 454-459
24. Evrard P, Cuq P, Robert B, Vian L, Pelegrin A, Cano JP. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 1999; 80: 465-470
25. Min JS, Kim NK, Park JK, Yun SH, Noh JK. A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer. Ann Surg Oncol 2000; 7: 674-679
26. Yamagata M, Mori M, Mimori K, Mafune KI, Tanaka Y, Ueo Y, Akiyoshi T. Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer. Br J Cancer 1999; 79: 565-569
27. Mimori K, Ueo H, Shirasaka C, Shiraishi T, Yamagata M, Haraguchi M, Mori M. Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis. Ann Oncol 1999; 10: 111-113
28. Akao S, Inoue K. PyNPase and DPD expression potentially predict response to 5′-DFUR treatment for node-positive breast cancer patients. Gan To Kagaku Ryoho 2003; 30: 1361-1364
29. Tazawa K, Sakamoto T, Kuroki Y, Yamashita I, Okamoto M, Katuyama S, Fujimaki M. Inhibitory effects of fluorinated pyrimidines, 5′-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose. Clin Exp Metastasis 1997; 15: 266-271
30. Monden T, Haba A, Amano M, Kanoh T, Tsujie M, Ikeda K, Izawa H, Ohnishi T, Sekimoro M, Tomita N, Okamura J, Monden M. PyNPase expression and cancer progression in the colorectum. Nippon Geka Gakkai Zasshi 1998; 99: 446-451